Pfizer

Pfizer Responds to Delaware Chancery Court Ruling

08 Nov 2025

Pfizer Inc. (NYSE: PFE) today issued the following statement in response to the Delaware Chancery Court’s decision denying Pfizer’s request for a temporary restraining order to prevent Metsera, Inc. f

Pfizer Files Lawsuit Against Metsera and its Directors and Novo Nordisk for Breach of Merger Agreement

01 Nov 2025

Pfizer Inc. today announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. in the Delaware Court of Chancery. The lawsuit asserts claims for breach o

Pfizer Receives Early Clearance from U.S. Federal Trade Commission for Metsera Acquisition

01 Nov 2025

Pfizer Inc. (NYSE: PFE) today announced the U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended

Pfizer Addresses Proposal for Metsera

30 Oct 2025

Pfizer Inc. (NYSE: PFE) is aware of the reckless and unprecedented proposal by Novo Nordisk A/S (NYSE: NVO) to acquire Metsera, Inc. (NASDAQ: MTSR). It is an attempt by a company with a dominant marke

Pfizer shares new survival data in non-metastatic prostate cancer

22 Oct 2025

The probability of survival at 8 years was an unprecedented 78.9% with XTANDI plus leuprolide versus 69.5% with leuprolide, in men with non-metastatic hormone-sensitive prostate cancer with high-risk

New long-term survival data in advanced lung cancer

22 Oct 2025

BRAFTOVI + MEKTOVI continued to show a substantial median overall survival benefit of 47.6 months in treatment-naïve patients with BRAF V600E-mutant metastatic non-small cell lung cancer after approxi

Unprecedented survival data in muscle-invasive bladder cancer

22 Oct 2025

TOKYO AND NEW YORK, October 18, 2025 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, “Astellas”) and Pfizer Inc. (NYSE: PFE) today announced positive results from the pivotal Phas

TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial

14 Oct 2025

Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 HER2CLIMB-05 trial of first-line combination therapy with the tyrosine kinase inhibitor TUKYSA ® (tucatinib) in patien

Pfizer to Highlight Advancements in Respiratory Health and Infectious Disease Research at IDWeek 2025

13 Oct 2025

Pfizer Inc. (NYSE: PFE, “Pfizer”) will present data across its infectious disease portfolio at the upcoming IDWeek 2025 congress, held in Atlanta from October 19-22, 2025. Data in 46 abstracts from co

Pfizer Declares Fourth-Quarter 2025 Dividend

10 Oct 2025

Board of Directors approves quarterly cash dividend of $0.43 per share Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2025 dividend on the company’

View details about the software product Informachine News Trackers